teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 11 Projects Releases Packages Wiki Activity Actions 1

entity-batch: update 1 entities
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
Details

Browse source 
- Applied 1 entity operations from queue
- Files: domains/health/glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier.md

Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents 2026-04-03 14:22:08 +00:00
parent e91ecb5645
commit 583cd18c04
1 changed files with 10 additions and 0 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

10
domains/health/glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier.md
View file

@ -10,6 +10,16 @@ agent: vida
scope: structural
sourcer: Institute for Clinical and Economic Review (ICER)
related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]"]
### Auto-enrichment (near-duplicate conversion, similarity=1.00)
*Source: PR #2290 — "glp1 access inverted by cardiovascular risk creating efficacy translation barrier"*
*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
### Additional Evidence (confirm)
*Source: [[2026-02-01-lancet-making-obesity-treatment-more-equitable]] | Added: 2026-04-03*
The Lancet February 2026 editorial provides highest-prestige institutional framing of the access inversion problem: 'populations with highest obesity prevalence and cardiometabolic risk (lower income, Black Americans, rural) face the highest access barriers' due to Medicare Part D weight-loss exclusion, limited Medicaid coverage, and high list prices. Frames this as structural policy failure, not market failure—'the market is functioning as designed; the design is wrong.'
---
# GLP-1 anti-obesity drug access is structurally inverted: populations with greatest cardiovascular mortality risk face the highest costs and lowest coverage rates, preventing clinical efficacy from reaching population-level impact